Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Issue : The Pharmaceutical Journal, 19/26 April 2014, Vol 292, No 7806/7

Sort by: Newest first Oldest first A-Z Z-A

  • Question from practice: Could you spot diabetic gastroparesis? Subscription

    Hyperglycaemia is a key factor in the pathophysiology of diabetic neuropathy, but other changes also contribute. In type 2 diabetes, dyslipidaemia and disturbances in neuronal insulin sensitivity are thought to play a major role. Changes in insulin signalling are important in patients with type 1 diabetes.

  • Pharmacists still relatively invisible in the media and the NHS Subscription

    19 APR 2014 By Andrew McCoig

    Zeshan Ahmed brings up the continuing problem of the absence of television media recognition of the profession (PJ, 12 April 2014, p400). This has been endemic since I became a pharmacist in 1970. We have never been acknowledged by any director of programming in any of the major TV companies or institutions as a worthy source of credible information on medicines. This effect is less pronounced on the radio ...

  • Improving survival rates for multi-drug resistant TB Subscription

    19 APR 2014 By Grania Brigden

    Jezza Neumann’s documentary “TB: return of the plague” (PJ 2014;292:296) highlighted many of the issues for patients on multi-drug resistant tuberculosis (MDR-TB) treatment and the dire need for better treatment options.

  • A retrograde step to 30-day packs Subscription

    19 APR 2014 By Peter McAuley

    I note with dismay the announcement in the PJ that the Femara packaging has been switched from a 28-pack to 30-day pack. (PJ 2014;292:292).

  • DM+D should reflect prescribing intentions Subscription

    19 APR 2014 0:00 By Andrew Paxton

    I am fortunate that I work in Cumbria, where the electronic prescriptions service is running well. However, the system relies on there being entries in the Dictionary of Medicines and Devices (DM+D) for the products prescribed. Some products do not appear because the prescribing is not specific enough, such as Gaviscon Advance without specifying the flavour. But one product that never appears is paracetamol caplets 500mg. This is because the product is considered to be just paracetamol ...

  • Professionalism lies with pharmacists, not pharmacies Subscription

    19 APR 2014 0:00 By Graham Walker

    I managed to struggle through the informative article on the issue of Boots pharmacists union recognition (PJ 2014;291:104). In essence, it seems to me that Boots seeks to negotiate with Boots Pharmacists’ Association, which does not deal with pay and conditions, and is fighting tooth and nail to avoid recognition of the PDA Union, which would ...

  • How drugs work: basic pharmacology for healthcare professionals’ 3rd edition, by Hugh McGavock. Pp ix+193 Price £24.99. Oxford: Radcliffe Publishing; 2013. ISBN 978 1 84619 478 8

    How drugs work: basic pharmacology for healthcare professionals Subscription

    17 APR 2014 15:52 By Kalliopi Dodou

    This third edition is a concise handbook of pharmacology, covering background knowledge and know-how of drug action in the human body.

  • ‘Fast exercise’, by Michael Mosley and Peta Bee. Pp 207. Price £7.99. London: Short book; 2013. ISBN 978 1 78072 198 9

    Fast Exercise Subscription

    17 APR 2014 15:46 By Rod Tucker

    If, like me, you thought that exercise will help you shed weight then think again. As the authors of this new book describe, out of all the benefits from exercise, weight loss is not one of them.

  • Mirvaso (brimonidine)

    Brimonidine gel launched for reduction of erythema associated with rosacea

    17 APR 2014 11:24

    Patients with rosacea can now be treated for the facial redness caused by the condition.

  • Tamiflu pack

    ABPI criticises Roche for withholding Tamiflu data from Cochrane reviewers

    17 APR 2014 10:54

    Roche, manufacturer of Tamiflu, should have complied with a reasonable request for data, says the ABPI

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.